Polatuzumab vedotin in untreated diffuse large B-cell lymphoma: one step forward, two steps back

2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...

Read more →

Tebentafusp in uveal melanoma: indication of a considerable additional benefit

 1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...

Read more →

Patisiran sodium in hereditary transthyretin amyloidosis: less benefit than vutrisiran

1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study.  ...

Read more →

Significant additional benefit of mavacamten in hypertrophic obstructive cardiomyopathy

1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...

Read more →

Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines

15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...

Read more →

Multiple sclerosis: hardly any evidence for good patient care

4 October 2023 - Even in the final report, many questions about the treatment of relapsing-remitting multiple sclerosis remain unanswered because ...

Read more →

Lisocabtagene maraleucel in second-line B-cell lymphoma: additional benefit for certain patients

1 September 2023 - On the basis of the available data, there is a hint of a non-quantifiable added benefit ...

Read more →

Upadacitinib in active Crohn's disease: no additional benefit proven due to a lack of comparative studies

1 August 2023 - Although biologics have been used in Crohn's disease for over 20 years, there are hardly any studies ...

Read more →

Trastuzumab deruxtecan: benefits also in HER2 low breast cancer

2 May 2023 - For patients with advanced HER2 low breast cancer, IQWiG sees an additional benefit that is partly considerable ...

Read more →

Olaparib in metastatic prostate cancer: added benefit for certain patients

17 April 2023 - Younger treatment naïve patients benefit. No relevant data were presented for previously treated patients. ...

Read more →

Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan

2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...

Read more →

Vutrisiran in hereditary transthyretin amyloidosis: hint of minor added benefit

17 January 2023 - Vutrisiran is approved for the treatment of patients with hereditary transthyretin amyloidosis with stage 1 or ...

Read more →

Pertuzumab and pertuzumab with trastuzumab in breast cancer: now a minor additional clinical benefit

2 January 2023 - Advantages in overall survival and in relapses often only become apparent after a long period of ...

Read more →

COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk

4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...

Read more →

Palbociclib combination in advanced breast cancer: again only disadvantages

5 October 2022 - For post-menopausal women with hormone receptor positive, HER2 negative breast cancer in the first line, there is ...

Read more →